Nyxoah S.A.

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

Nyxoah will release third quarter 2026 financial results on Thursday, November 5, 2026. Management will host a conference call that day at 10:30 pm CET / 4:30 pm ET, with a webcast available on the company's investor relations page. No financial figures were disclosed in this scheduling announcement.

•6d ago

REG-Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

Nyxoah SA announced it will release third quarter 2026 financial results on Thursday, November 5, 2026, with a conference call that day at 10:30 pm CET / 4:30 pm ET. The release is a scheduling notice only — no results, guidance, or other financial figures were provided. A webcast will be available via the company's investor relations page, with an archived replay afterward.

•6d ago

CVRx Appoints John Landry as Chief Financial Officer

CVRx appointed John Landry as Chief Financial Officer; he joins October 12, 2026 and assumes the role the day after the company files its Form 10-Q for the quarter ending September 30, 2026. Landry brings more than two decades of medical device finance leadership, currently serving as CFO of Nyxoah SA and previously as Senior Vice President and CFO of Vapotherm, where he led the company's IPO. Outgoing CFO Jared Oasheim, with CVRx since 2015 and CFO through its IPO, will remain through a transition period under his previously disclosed transition agreement. The hire resolves a previously disclosed CFO vacancy with a successor who has commercial and capital markets experience, supporting continuity as CVRx scales Barostim in heart failure.

•1mo ago

Nyxoah Announces Chief Financial Officer Transition

Nyxoah's CFO John Landry will step down effective October 2, 2026, to pursue another professional opportunity, with Loïc Moreau taking over as interim CFO while the company searches for a permanent successor. Moreau is a strong internal bridge: he joined Nyxoah in 2022 as CFO, moved to President International in 2024, and brings 20+ years of finance experience including senior roles at GSK. CEO Olivier Taelman cited that continuity as supporting a smooth transition on the company's growth strategy and path to profitability. Alongside the transition, Nyxoah reaffirmed full-year 2026 guidance: net revenue of €36-40 million, gross margin of 60-62%, total operating expenses of €99-102 million, and non-GAAP cash operating expenses of €88-90 million.

•1mo ago

REG-Nyxoah Announces Chief Financial Officer Transition

Nyxoah announced that CFO John Landry will step down effective October 2, 2026, to pursue another professional opportunity. Loïc Moreau, the company's President International who previously served as CFO from 2022 to 2024, becomes Interim CFO while a search for a permanent successor proceeds, with CEO Olivier Taelman emphasizing continuity and confidence in a smooth transition. The company simultaneously reaffirmed its full-year 2026 guidance: worldwide net revenue of €36 million to €40 million, gross margin of 60% to 62%, total operating expenses of €99 million to €102 million, and non-GAAP cash operating expenses of €88 million to €90 million.

•1mo ago

Information on the total number of voting rights and shares

Nyxoah SA issued 1,767,402 new shares on August 20, 2026, through a contribution in kind of a receivable held by a holder of convertible bonds issued in December 2025. Following this issuance, the company's total number of voting rights now stands at 101,840,217, all relating to ordinary shares. The disclosure also detailed the company's 225 outstanding convertible bonds, which could result in up to 13.41 million additional voting rights if converted at the Relevant Share Settlement Price of EUR 1.25.

•2mo ago

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026

Nyxoah announced that it will release its financial results for the second quarter of 2026 on Wednesday, August 5, 2026. Management is scheduled to host a conference call to discuss the results beginning at 4:30pm ET on the same day, accessible via the Investor Relations page of the company's website. The company's lead product is the Genio system, a neurostimulation therapy for Obstructive Sleep Apnea which received FDA approval in August 2025.

•3mo ago

REG-Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026

Nyxoah SA announced that it will release its financial results for the second quarter of 2026 on Wednesday, August 5, 2026. Management will host a conference call to discuss the results that same day at 4:30pm ET. The company specializes in the Genio system, a neurostimulation therapy for Obstructive Sleep Apnea that received FDA approval in August 2025.

•3mo ago

Information on the total number of voting rights and shares

Nyxoah SA disclosed the issuance of 146,531 new shares on June 30, 2026, resulting from the exercise of restricted share units. Following the issuance, the company's total voting rights stand at 100,072,815, with a corresponding share capital of EUR 7,075,152.31. The filing also detailed the company's outstanding convertible bonds, noting that full conversion of the 225 bonds could add 12,618,243 voting rights.

•4mo ago

REG-Information on the total number of voting rights and shares

Nyxoah SA updated its total voting rights to 100,072,815 following the issuance of 146,531 new shares from exercised restricted share units. The filing confirms a share capital of EUR 7,075,152.31 and details 3,731,884 outstanding subscription rights. Additionally, the company disclosed 225 convertible bonds that could add up to 12,618,243 voting rights if fully converted at the current price of EUR 1.48 per share.

•4mo ago

REG-Publication relating to transparency notifications

Nyxoah disclosed transparency notifications revealing that entities controlled by Orin Hirchman crossed the 10% ownership threshold on June 10, 2026. The notification indicates that AIGH Investment Partners and affiliated funds hold 14,534,880 voting rights, representing 14.55% of the company's total issued shares. Separately, Resmed Inc. reported a passive downward crossing of the 3% threshold, reducing its holding to 1,943,828 voting rights, or 1.95%.

•4mo ago

Nyxoah to Host Investor Day in New York on July 8, 2026

Nyxoah SA announced it will host an Investor and Analyst Day on July 8, 2026, at the Bank of America Tower in New York. The event agenda focuses on the U.S. commercial execution of the Genio system, including second-quarter KPIs, the reimbursement landscape, and the company's path to profitability. Management will be joined by external clinical experts and JD Lymon Group, with the event available via live webcast.

•4mo ago

REG-Nyxoah to Host Investor Day in New York on July 8, 2026

Nyxoah SA announced it will host an Investor and Analyst Day in New York on July 8, 2026, to discuss U.S. commercial execution and growth strategy. The agenda highlights include a review of Genio U.S. launch momentum, the reimbursement landscape, and the company's path to profitability. The event will feature participation from the leadership team, board members, and external clinical experts, with a live webcast available for investors.

•4mo ago

Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026

NYXOAH SA has issued a notice convening an extraordinary shareholders' meeting for July 9, 2026. The primary agenda item is to renew the authorization for the board of directors to increase the share capital within the framework of authorized capital for a period of five years. This is a standard corporate governance procedure required under Belgian law to maintain the board's flexibility for future capital raises, without implying any immediate issuance or dilution.

•4mo ago

REG-Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026

NYXOAH SA has convened an extraordinary shareholders' meeting for July 9, 2026, to renew the authorization for the board of directors to increase share capital. The proposal allows the board to issue new shares up to an aggregate amount equal to the company's current capital over the next five years, subject to a 75% shareholder vote. This is a routine corporate governance update to maintain capital flexibility; no new shares are being issued at this time.

•4mo ago

REG-Publication relating to transparency notifications

Nyxoah SA published transparency notifications revealing that Robert Taub and Pierre-Edouard Stérin increased their respective holdings to 14.45% and 7.23% of voting rights, crossing the 10% and 5% disclosure thresholds. Conversely, Cochlear Limited's stake dropped to 5.85% due to dilution from a recent capital increase, with underwriters holding an option for an additional 8.28 million shares. Bank of America and its affiliates also reported crossing the 3% threshold, while Gilde Healthcare notified a downward crossing of the 3% threshold.

•4mo ago

Information on the total number of voting rights and shares

Nyxoah SA published a regulatory disclosure detailing its total voting rights and share capital following the issuance of 55,232,558 new shares. The issuance was part of a previously announced underwritten public offering in the United States, which included a private placement component for qualified investors. The company now has 99,926,284 ordinary shares carrying voting rights, with an additional 12,618,243 shares potentially issuable upon conversion of 225 outstanding convertible bonds.

•4mo ago

REG-Information on the total number of voting rights and shares

Nyxoah SA published a regulatory disclosure detailing its total voting rights and share capital following the issuance of 55,232,558 new shares. The issuance was part of a previously announced underwritten public offering in the United States, which included a private placement to qualified institutional investors. The company now has 99,926,284 ordinary shares carrying voting rights, with an additional 12,618,243 shares potentially issuable upon conversion of 225 outstanding convertible bonds.

•4mo ago

REG-Nyxoah Announces Closing of Underwritten Public Offering

Nyxoah closed an underwritten public offering of 55.2 million ordinary shares at $1.72 per share, generating gross proceeds of approximately $95 million. The company plans to use the net proceeds to expand commercialization in the United States, fund R&D for Genio system upgrades, and advance commercialization in initial target markets outside the US. Additionally, Nyxoah intends to draw EUR 13.8 million from the second tranche of its European Investment Bank loan in Q2 2026 to support its liquidity needs.

•4mo ago

Nyxoah Enters New Chapter of Long Term Value Creation

Nyxoah announced the commencement of a leadership transition process to appoint a new U.S.-based CEO. Outgoing CEO Olivier Taelman, who led the company for seven years, will remain fully engaged during the transition to support daily operations and onboarding. The Board stated that a U.S.-focused leadership structure will position Nyxoah for its next phase of growth in the rapidly expanding Obstructive Sleep Apnea market.

•4mo ago

REG-Nyxoah Enters New Chapter of Long Term Value Creation

Nyxoah announced the commencement of a leadership transition process to appoint a new U.S.-based CEO. Outgoing CEO Olivier Taelman, who led the company for seven years, will remain fully engaged during the transition to support daily operations and onboarding. The Board launched a search for a U.S.-based leader to accelerate commercial traction for its Genio device in the United States, citing strengthened financial resources and accelerating U.S. momentum.

•4mo ago

Information on the total number of voting rights and shares

Nyxoah SA issued 1,031,323 new shares on May 20, 2026, in connection with the contribution in kind of a receivable held by the holder of its convertible bonds. The company’s total share capital is now EUR 6,521,361.42, with 44,693,726 ordinary shares carrying voting rights. The disclosure also notes 225 outstanding convertible bonds with a nominal value of EUR 83,000 each, which could result in up to 8.57 million additional shares if converted at the relevant settlement price.

•5mo ago

REG-Information on the total number of voting rights and shares

Nyxoah SA published a regulatory disclosure detailing its total voting rights and share capital following the issuance of 1,031,323 new shares. The new shares were issued in connection with the contribution in kind of a receivable held by the holder of convertible bonds issued in December 2025. The company now has 44,693,726 voting rights and a share capital of EUR 6.52 million, with 225 convertible bonds outstanding that could potentially dilute voting rights further upon conversion.

•5mo ago

REG-Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum

Nyxoah hosted the Flemish Investors Federation at its LégiaPark campus in Liège to discuss commercial progress in the U.S. less than a year after FDA approval. CEO Olivier Taelman highlighted the strength of the company's Belgian industrial footprint and the scaling of manufacturing capacity at the new facility. The event also included a presentation by Hyloris Pharmaceuticals, a neighboring listed company on the same campus, showcasing the local life sciences ecosystem.

•5mo ago

Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026

Nyxoah announced it will release its first quarter 2026 financial results on Tuesday, May 12, 2026. Management will host a conference call to discuss the results that day at 4:30pm ET. The company develops the Genio system, a neurostimulation therapy for Obstructive Sleep Apnea.

•6mo ago

REG-Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026

Nyxoah announced that it will release its first quarter 2026 financial results on Tuesday, May 12, 2026. Company management is scheduled to host a conference call to discuss these results at 4:30pm ET on the same day. The company specializes in the Genio system, a neurostimulation therapy designed to treat Obstructive Sleep Apnea.

•6mo ago